BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2018;61:4052-66. [PMID: 29653491 DOI: 10.1021/acs.jmedchem.8b00082] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Nasiri AH, Nasiri HR. Polymerase assays for lead discovery: An overall review of methodologies and approaches. Anal Biochem 2018;563:40-50. [PMID: 30291837 DOI: 10.1016/j.ab.2018.09.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Abdallah M, Hamed MM, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch AKH, Abdel-Halim M, Abadi AH. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier. Eur J Med Chem 2021;229:114034. [PMID: 34959173 DOI: 10.1016/j.ejmech.2021.114034] [Reference Citation Analysis]
3 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Stalgis C, Deepak P, Mehandru S, Colombel JF. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology 2021;161:394-9. [PMID: 33961886 DOI: 10.1053/j.gastro.2021.04.068] [Reference Citation Analysis]
5 Meanwell NA, Georg GI, Wang S. The 2020 Nobel Prize in Physiology or Medicine. J Med Chem 2020;63:13197-204. [PMID: 33147952 DOI: 10.1021/acs.jmedchem.0c01877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Tyagi M, Begnini F, Poongavanam V, Doak BC, Kihlberg J. Drug Syntheses Beyond the Rule of 5. Chem Eur J 2020;26:49-88. [DOI: 10.1002/chem.201902716] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
7 Kim BW, Lee H, Keum G, Kim BM. Structure-activity relationship (SAR) studies on the mutagenic properties of 2,7-diaminofluorene and 2,7-diaminocarbazole derivatives. Bioorg Med Chem Lett 2021;31:127662. [PMID: 33227415 DOI: 10.1016/j.bmcl.2020.127662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Voight EA, Greszler SN, Kym PR. Fueling the Pipeline via Innovations in Organic Synthesis. ACS Med Chem Lett 2021;12:1365-73. [PMID: 34531945 DOI: 10.1021/acsmedchemlett.1c00351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Han J, Remete AM, Dobson LS, Kiss L, Izawa K, Moriwaki H, Soloshonok VA, O’hagan D. Next generation organofluorine containing blockbuster drugs. Journal of Fluorine Chemistry 2020;239:109639. [DOI: 10.1016/j.jfluchem.2020.109639] [Cited by in Crossref: 48] [Cited by in F6Publishing: 12] [Article Influence: 24.0] [Reference Citation Analysis]
10 Song J, Shao PL, Wang J, Huang F, Zhang X. Asymmetric hydrogenation of 1,4-diketones: facile synthesis of enantiopure 1,4-diarylbutane-1,4-diols. Chem Commun (Camb) 2021;58:262-5. [PMID: 34878456 DOI: 10.1039/d1cc05359k] [Reference Citation Analysis]
11 You Y, Kim HS, Park JW, Keum G, Jang SK, Kim BM. Sulfur( vi ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. RSC Adv 2018;8:31803-21. [DOI: 10.1039/c8ra05471a] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ivashchenko AA, Ivanenkov YA, Aladinskiy VA, Karapetian RN, Koryakova AG, Ryakhovskiy AA, Mitkin OD, Kravchenko DV, Savchuk NP, Zagribelnyy BA, Ivashchenko AV. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors. Bioorg Med Chem 2020;28:115716. [PMID: 33069072 DOI: 10.1016/j.bmc.2020.115716] [Reference Citation Analysis]
13 Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gadhachanda VR, Eastman KJ, Wang Q, Phadke AS, Patel D, Yang W, Marlor CW, Deshpande M, Huang M, Wiles JA. Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity. Bioorg Med Chem Lett 2018;28:3463-71. [PMID: 30290989 DOI: 10.1016/j.bmcl.2018.09.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huo X, Hou D, Wang H, He B, Fang J, Meng Y, Liu L, Wei Z, Wang Z, Liu FW. Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives. Eur J Med Chem 2021;224:113684. [PMID: 34256126 DOI: 10.1016/j.ejmech.2021.113684] [Reference Citation Analysis]
16 Leeson PD, Bento AP, Gaulton A, Hersey A, Manners EJ, Radoux CJ, Leach AR. Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. J Med Chem 2021;64:7210-30. [PMID: 33983732 DOI: 10.1021/acs.jmedchem.1c00416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ramdas V, Talwar R, Banerjee M, Joshi AA, Das AK, Walke DS, Borhade P, Dhayagude U, Loriya R, Gote G, Bommakanti A, Sivaram A, Agarwal G, Goswami A, Nigade P, Mehta M, Patil V, Modi D, Kumar H, Mallurwar S, Dash A, Modi F, Kuldharan S, Srivastava P, Singh M, Narasimham L, Gundu J, Sharma S, Kamboj RK, Palle VP. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem 2019;62:10563-82. [PMID: 31710479 DOI: 10.1021/acs.jmedchem.9b01562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Liu B, Gai K, Qin H, Wang J, Liu X, Cao Y, Lu Q, Lu D, Chen D, Shen H, Song W, Mei J, Wang X, Xu H, Zhang Y. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor. J Med Chem 2020;63:5312-23. [PMID: 32293179 DOI: 10.1021/acs.jmedchem.0c00082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zhou WX, Chen C, Liu XQ, Li Y, Lin YL, Wu XT, Kong LY, Luo JG. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem 2021;210:112980. [PMID: 33176943 DOI: 10.1016/j.ejmech.2020.112980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem 2019;167:245-68. [PMID: 30772607 DOI: 10.1016/j.ejmech.2019.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Voight EA, Greszler SN, Hartung J, Ji J, Klix RC, Randolph JT, Shelat BH, Waters JE, DeGoey DA. Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chem Sci 2021;12:10076-82. [PMID: 34349971 DOI: 10.1039/d1sc02396a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Qin Z, Yan A. QSAR studies on hepatitis C virus NS5A protein tetracyclic inhibitors in wild type and mutants by CoMFA and CoMSIA. SAR QSAR Environ Res 2020;31:281-311. [PMID: 32208783 DOI: 10.1080/1062936X.2020.1740889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]